It is now well established that regulatory helper and suppressor T lymphocytes play a critical role in determining the magnitude and nature of a variety of immune responses. Different lines of experiments indicate that T ceils recognize not only surface-bound antigens, but also idiotypic (1, 2) and allotypic (3) determinants on helper T cells and/or B lymphocytes. In addition, it is clear that the antigenrecognition function of several classes of T lymphocytes, including helper cells, cytolytic T lymphocytes (CTL)1, and the effector cells of delayed hypersensitivity (4), is restricted by the major histocompatibility gene complex (MHC). The MHCrestricted collaboration between antigen-specific helper T and B lymphocytes (5, 6) implies that antigen-specific T cells recognize receptor-bound antigen in some form of an association with MHC gene products, although it is difficult to demonstrate directly such an associative recognition mechanism in normal immune-cell populations.
cyte populations containing hapten-specific CTL on the function of hapten-binding myelomas in the presence of soluble hapten-protein conjugates. In this system, myeloma cells are used as a homogeneous target cell population analogous in function and receptor expression to normal B lymphocytes or to antibody-secreting cells. In fact, recent experiments strongly suggest that myelomas are physiologically valid model systems for analyzing the regulation of normal immunocompetent lymphocytes (11, 12) . Thus, tolerogenic antigens (13) , antigen-antibody complexes (14) , carrierspecific helper and suppressor T cells (15, 16) , idiotype-specific T cells (17, 18) , and alloreactive T cells (19) have all been shown to be capable of modulating myeloma cell function. The specific experimental protocol we have used is to stimulate BALB/c lymphocytes with syngeneic TNP-modified cells, and then to examine the effect of the TNP-reactive T cells generated in this manner on the TNP-binding BALB/c myeloma, MOPC 315, in the presence of TNP-protein conjugates. We have used assays of antibody secretion by the myeloma as a readout system for measuring the effect of CTL. The rationale for this approach is that the inhibition of target-cell function seems to represent a pre-lytic effect of CTL, and is a far more sensitive assay for CTL activity than 51Cr release or trypan blue dye exclusion methods (19, 20) . The basic observations that have been made are that TNP-reaetive T cells markedly inhibit antibody secretion by the myeloma in the presence of TNP-protein conjugates, although by ~tCr-release assays, the lysis of myeloma targets can be detected only if the targets are TNP modified and can not be detected in the presence of soluble antigen. The T cells responsible for this functional inhibition possess the phenotypic characteristics of CTL, are hapten specific and H-2 restricted in their function, and suppress only myeloma cells that bear specific receptors for the hapten. In addition, preliminary experiments indicate that TNP-specific CTL also inhibit primary antibody response to TNP-proteins in vitro. These findings are discussed in relation to the mechanisms of T lymphocyte-target cell interactions and the possible physiologic immunoregulatory role of hapten-reactive T lymphocytes.
Materials and Methods

Myeloma Cell Lines, Anttgens
The myeloma cell hnes used in this study are listed in Table I The majority of the experiments have been done with tissue-culture-adapted MOPC 315 cells, which were used in previous studies and whose charaeterisucs have been described in detail (13) Briefly, the cells secrete an IgA, X2 antibody specific for TNP and 2,4-dinitrophenyl TNP conjugates of keyhole limpet hemocyanm (KLH), bovine y-globuhn (BGG), and bovine serum albumin (BSA) were prepared by the method of Ballas and Henney (10) using 2,4,6-trmitrobenzene sulfomc acid (TNBS) in 0.4 M borate buffer, pH 9. The conjugates used m these experiments were TNPlvKLH, TNP2sKLH, and TNPa0KLH (17, 28 , and 30 tool TNP, respectively, per 100,000 moi wt of KLH), TNP52BGG (52 mol TNP/mol of BGG), and TNP~BSA (24 tool TNP/mol of BSA) DNPz0KLH was prepared by incubating KLH with 2,4-dimtro-l-fluorobenzene in 1% sodium carbonate, p-Azobenzene arsonate (ABA) conjugates of KLH were prepared as described by Nisonoff (21) . The double conjugate TNP-ABA-KLH was prepared by incubating ABA-KLH with TNBS following the method of Ballas and Henney (10) as described above.
Generatzon of Hapten-reactwe T Cells and Assay for Cytolysis
Normal BALB/c spleen lymphocytes (7 × 10 e) were stimulated in vitro with 6 × 106 syngeneic, 1,500-tad x-irradiated, TNBSmodified, erythrocyte-free splenocytes as described previously (22) Cultures were carried out for 5 d in 2 ml RPMI-1640 supplemented with penicillin, streptomycin, and 10% fetal calf serum (FCS) (Grand Island Biological Co., Grand Island N. Y.) in 16-mm Linbro wells (Linbro Chemical Co., Hamden, Conn.) at 37°C in a humidified atmosphere of 5% CO~. In some experiments, animals were primed subcutaneously 6-7 d previously with 3 × 107 TNBSmodified syngenelc cells, and their spleen lymphocytes boosted in vitro as described above. For generating DNP-and ABA-reactive T lymphocytes, animals were always primed subcutaneously with hapten-modified cells and spleen cells boosted in vitro, as described previously (23, 24) . Such stimulated cells are referred to as anti-hapten effector lymphocytes or hapten-speclfic CTL, their detailed characterization is described in Results In addition, m all experiments spleen cells were cultured in parallel without hapten-modified stimulators (referred to as unstimulated lymphocytes). In some experiments, responder spleen cells were obtained from BALB/c mice that had been injected with 100 mg/kg eyelophosphamide intraperitoneally 2 d earlier. TNP-specific CTL were also induced in vivo by the method of Rollinghoff et al (25) Briefly, BALB/c mice were injected with 100 mg/kg eyclophospbamide intraperitoneally, and 7 3 d later, were immunized in the hind footpads with 3 × 10 TNP-modified, 1,500-rad xirradiated syngeneic spleen cells. Draining lymph nodes harvested 4 d later were used as the source of TNP-specified CTL Unstimulated lymphocytes were obtained from lymph nodes of cyclophosphamlde-pretreated mice that were either not immunized or were injected in footpads 7 with 3 × 10 unmodified syngeneic splenocytes.
Cytolytic activity of cultured cells was measured by 51Cr-release assays, as described previously (22) . For BALB/c (H-2 a) cells, the targets used were syngeneie 51Cr-labeled MOPC 315 or P 815 (DBA/2) mastocytoma cells, modified with 10 mM TNBS (for assessing TNP-reactive CTL), 10 mM DNBS (for anti-DNP CTL), or p-azobenzene arsanilate (for anu-ABA CTL), all of which have been previously described (22) (23) (24) AntI-TNP CTL gave comparable levels of lysls using TNP-modified MOPC 315 or P 815 cells as targets For B 10 BR (H-2 k) effectors, the targets were SXCr-labeled TNBS-modified RDM-4 (AKR) tumor cells Assays were done at effector'target (E:T) ratios ranging from 4:1 to 100-1, for 4 h at 37°C in 10-× 75-mm glass tubes, after which the 5aCr released into the supernate was counted Results are expressed as percent specific lysis = (E -C)/(FT -C), where E --release in experimental groups with CTL, C = background release from targets with normal spleen cells, and FT --maximal release after four cycles of freezing and thawing.
Myeloma-Cell Cultures and Assays for Anttbody Secretwn
Viable tissue-culture-adapted myeloma cells (>90% viable by trypan blue dye exclusion) were purified by centrifugatlon over FicollIsopaque (Pharmacia Free Chemicals, Div. of Pharmacia, Ine, Piscataway, N J ) (13) , and ascitic cell lines were freed oferythrocytes by lysis with Tris-buffered 0.83% ammonium choride, pH 7.4 In all experiments, 105 myeloma cells in triplicate were first incubated with or without the appropriate concentration of antigen (hapten conjugates of KLH) in RPMI-1640 with penicillin, streptomycin, 10% FCS, 5 × 10 -s M 2-mercaptoethanol, and 10 mM Hepes These incubations were done in round-bottomed microculture plates (Linbm Chemical Co.) at 37°C in 5% CO2 At the end of 60 rain, lymphocytes generated by in vitro culture as described above were added to a final vol of 0.2 ml, and the incubations continued for a further 4-48 h At the end of this coculture, cells were harvested, washed three times, and assayed for antibody secretion as described below. In all experiments, control groups of myeloma cells alone and myeloma cells with antigen alone were included; the antigens chosen have been shown to have no significant effect on myeioma growth or function ( [13] ; and these experiments).
Antibody secretion was measured by a reverse hemolytic plaque assay (26) , the details of which have been described previously (13, 19) . Briefly, 1/50ths or 1/100ths of eacda washed culture were mined with 20 pl of 30% sheep erythrocytes coated with staphylococcal protein A, 20/~i of an optimal concentration of developing serum, 20 pl of a 1:3 dilution of guinea pig complement (Pel-Freeze Biologicals Inc., Rogers, Ark.), and 300 gl of 0.5% agarose in Hanks' balanced salt solution. The mixture was smeared on a 10-era plastic dish, incubated at 37°C m a humidified atmosphere for 5-6 h, and the plaques counted. The developing sera used were: 1:50 dilution of rabbit anti-M315 IgA for MOPC 315, S107, and TEPC 15 cells (all IgA secretors), 1:50 rabbit anti-MPC 11 for MPC 11 cells, and 1:50 rabbit anti-104E for MOPC 104E cells Each myeloma cell line produced plaques only with the appropriate developing serum; moreover, cultured lymphocytes by themselves did not produce significant numbers of plaques under these conditions. All results are expressed as plaque-forming cells (PFC)/culture Statistical analyses and determinations of the percent inhibition caused by hapten-reactive cells are calculated using groups lacking the effector lymphocytes as controls.
Binding of tZSl-labeled Antzgens to Myeloma Cells. The techniques have been described previously (27) . Briefly, TNP-KLH was trace-labeled with 12s -• -125 I by the chloramme T method. Free I was removed by exhaustive dialysts, and >90% of the radioactivity was precipitable m 10% trichloroacetic acid. 10 n myeloma cells were incubated in duplicate with various concentrations of 125I-labeled antigen in 0.2 ml of RPMI-1640 with supplements in 12-× 75-ram plastic tubes at 37°C in 5% CO2. After 1-2 h, cells were washed four times, and the cell-associated radioactivity measured in a Beckman Biogamma II -/-counter (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif). Standards wtth known amounts of lasI-labeled antigen were mcluded, and results are expressed as nanograms of antigen bound/'I0 b cells. For ascitic lines, macrophages were depleted by two cycles of adherence to plastic dishes, each for 45 min at 37°C, before antigen incubations.
lnductwn of Antz-TNP Anttbody Responses In Vttro. A microculture system was used for generating primary anti-TNP antibody responses (28). 5 × 10 n normal BALB/c spleen cells were cultured with TNP-KLH in 0.2 ml of RPMI-1640 with supplements as described above. Cultures were done in triplicate in fiat-bottomed microculture plates (Linbro Chemical Co.) in 5% CO2 at 37°C for 4 d, after which each well was harvested, washed twice, and anti-TNP PFC assayed by the slide modification of the Jerne method using TNP-coated sheep erythrocytes as indicator cells. Preliminary experiments established that, in our hands, the optimal concentration of TNP-KLH was 20-25 p.g/ml; unconjugated KLH elicited no response; the PFC response was T cell dependent; only IgM PFC were observed; and the response was TNP specific (>95% inhibttion with 3 × 10 -4 M TNP in the form of TNP~BSA).
Other Techmques. Effector lymphocytes were treated with anti-Thy-1 serum and complement as follows' tn vitro generated effector lymphocytes were treated with a monoclonal anti-Thy-1.2 antibody (a gift of Dr. Ann Rothstein, Massachusetts Institute of Technology), followed by rabbit complement (Pel-Freeze Biologicals Inc ). Cells were washed, counted with trypan blue, and used m cocultures. Effector cells were also treated with a monoclonal anti-Ly-2 2 antibody (a gift of Dr Paul Gottlieb, Massachusetts Institute of Technology) plus complement Controls consisted of complement treatment alone.
Results
Effect of TNP-reactwe Lymphocytes on MOPC 315 Cells.
In the initial series of experiments, BALB/c spleen cells stimulated in vitro with syngeneic TNP-modified splenocytes were tested for their ability to lyse 51Cr-labeled MOPC 315 cells in the presence of 50-100 pg/ml of TNP-KLH or TNP-BGG. Although such stimulated lymphocytes efficiently lysed TNP-modified MOPC 315 ceils, we were unable to detect any cytolysis of MOPC 315 targets incubated with soluble hapten-protein conjugates in a 4-h assay. In addition, MOPC 315 cells incubated with soluble antigen could not serve as cold targets to block the iysis of 51Cr-labeled TNP-modified MOPC 315 targets (data not shown). We then tested the effect of this anti-TNP CTLcontaining lymphocyte population on antibody secretion by MOPC 315 cells in the presence of TNP-KLH, an antigen which by itself does not affect MOPC 315 cell function. As shown in Table II , TNP-reactive lymphocytes (anti-TNP effector cells) significantly suppress IgA secretion by the myeloma cells in the presence of 10 or 50 #g/ml of TNP-KLH, whereas BALB/c splenocytes cultured in parallel, but without TNP-modified stimulators (unstimulated effector cells), are not suppressive. In addition, the TNP-reactive cells capable of inhibiting myeloma function are radioresistant, and can also be generated by in vitro stimulation of spleen cells from mice pretreated with 100 mg/kg of cyclophosphamide (Cyclo) (Table II) . Moreover, TNP-reactive cells are incapable of suppressing MOPC 315 cells in the absence of soluble antigen (Table III) . In most of the experiments, the degree of suppression observed is 40-65%. This may be because only 50-75% of MOPC 315 cells express TNP-specific surface receptors by rosette assays. Attempts to determine if PFC are present only in the receptor-bearing fraction or if they are distributed among receptor-positive and -negative myeloma cells have produced inconclusive results so far. In some experiments, we have found that BALB/c spleen cells cultured in FCS-containing media without additional stimulators are suppressive for MOPC 315 cells, but this suppression is seen with or without the presence of TNP-proteins. This nonspecific suppression is eliminated by irradiating the effector cells, a procedure that has no effect on the lyric activity of TNP-reactive cells. Moreover, the consistent inability of anti-TNP effectors to suppress MOPC 315 cells in the absence of soluble antigen provides an additional specificity control.
In addition to the inhibition of IgA secretion described above, cocultures of MOPC 315 cells with TNP-KLH and anti-TNP effector lymphocytes show a 15-25% reduction in viable myeloma-cell recovery after 24 h. After washing and reculture in fresh medium for 2-3 d, viable MOPC 315 cell recovery in these groups is reduced by 40-50% compared to groups with myeloma cells alone or myeloma cells and anti-TNP effectors without antigen. Taken together, these results suggest that the functional suppression of myeloma targets is a pre-lytic event reduced by the CTL, eventually resulting in reduced viable myeloma-cell recovery. Because, in this system, measurement of myeloma-cell function gives the most consistent and reproducible results, and because a similar assay has been used by other investigators to study CTL-target cell interactions (19, 20) , we have used PFC assays to analyze the nature of the interaction between anti-TNP effector cells and myeloma targets, in all subsequent experiments. Table II have shown that the TNP-reactive lymphocytes that suppress MOPC 315 cell function are radioresistant, and their precursors are insensitive to Cyclo These cells are T lymphocytes, as judged by their sensitivity to treatment with anti-Thy-l.2 serum and complement (Table  IV) and their nonadherence to nylon wool (data not shown). Moreover, the cells bear Ly-2.2 antigens, as shown by antiserum and complement treatment (Table IV) . In a series of kinetics and dose-response experiments, we have found that significant suppression requires >4 h coculture of 10s-3 X 105 effector lymphocytes with 10 ' Effector cells were also-(a) generated with spleen cells from mice pretreated with Cyclo, or (b) x-irradiated (I,500 rad) before adding to myeloma targets. * Calculated by Student's t tests, using groups that contained myeloma cells and equivalent concentration of TNPj7KLH without effector cells as controls. ~: Determined using groups that contained myeloma cells and anttgen only as controls (i e, 100% response) § NS, not sigmficant (P > 0.05) ]1 Spontaneous release was 8 4%, unmodified SICr-labeled targets showed no significant lysis myeloma targets, and is consistently seen after 24 or 48 h (data not shown). Moreover, the anti-TNP effector cells can he generated by in vitro stimulation in 0.5% syngeneic mouse serum or 2% rat serum, indicating that their activity is not related to the FCS in the culture medium. 10 ~ MOP(: 315 cells were cultured for 24 h with or wkthout TNP-KLH and 1,500-rad x-irradiated BALB/c anti-TNP effector cells which were generated m vitro, and treated as shown C, complement * Calculated as in Table II :~ NS, not slgmficant § Spontaneous SlCr release 9 3% lymphocytes are H-2 restricted (similar to hapten-specific CTL described in other systems [7, 9, 10, [22] [23] [24] ), we tested the effects of CTL generated with spleen lymphocytes of different mouse strains on the myeloma targets. As shown in Table V restriction, we attempted to block the effect of BALB/c anti-TNP effector lymphocytes on MOPC 315 cells with cold targets; in this system, cold targets refer to tumor ceils that do not secrete IgA and are, therefore, not detected in the PFC assay. As shown in Table VI , TNP-modified MPC 11 and P815 (H-2 a) cells block the suppression of MOPC 315 cells by BALB/c anti-TNP CTL in the presence of TNP-KLH, whereas TNP-modified X5563 (H-2 k) or unmodified "cold targets" have no effect. These experiments establish that the anti-TNP effector cells detected in this system are H-2 restricted, and, taken together with the phenotypic characteristics detailed above, strongly suggest that the effector ceils are, indeed, hapten-reactive CTL.
Properttes of TNP-reactwe Effector Cells. The data in
H-2 Restnctzon of Ant,-TNP Effector Cells. To determine if the anti-TNP effector
Hapten Speczficzty of CTL. The experiments described above have demonstrated that inhibition of MOPC 315 cell function is seen with TNP-reactive but not with unstimulated cells, and only in the presence of appropriate TNP-protein conjugates, suggesting that the phenomenon is hapten-specific. As a more stringent control for specificity, T cells were generated by priming in vivo followed by in vitro stimulation with DNP-and TNP-modified syngeneic splenocytes. These hapten-reactive CTL were tested for cytolysis of hapten-modified 5XCr-labeled targets and for their effects on MOPC 315 cells in the presence of DNP-KLH or TNP-KLH. In our hands, anti-DNP CTL lyse both DNP-and TNP-modified syngeneic targets, whereas anti-TNP CTL lyse only TNP-modified targets (Table VII) (R. Finberg, M.-S. Sy, M. I. Greene, and S. J. Burakoff. Manuscript in preparation.) Consistent with this pattern, TNPspecific CTL inhibit MOPC 315 cells only in the presence of TNP-KLH, whereas DNP-specific CTL cause significant suppression in the presence of both haptenprotem conjugates, TNP-KLH and DNP-KLH (Table VII) . Using antigens trace- Table II ; groups showing significant inhibition are ltalicmed In all experiments cold targets alone or with TNP-specific CTL, but without TNPa0KLH, had no effect on IgA PFC ("Cold targets" refers to tumor cells not secreting IgA ) * NS, not significant labeled with 125I, we have found that at equivalent concentrations comparable amounts of DNP20KLH and TNP2aKLH are bound to MOPC 315 cells (data not shown). Therefore, the differences in the effects of DNP-and TNP-specific CTL cannot be attributed to differences in the amount of antigen bound to the myeloma targets and presumably reflect inherent differences in the recognition or reactivity patterns of the T cells themselves.
Requzrement for Hapten-bmdmg Receptors on Myeloma Targets. To determine if non-TNP binding H-2 d myelomas incubated with TNP-KLH could also be inhibited by
TNP-specific CTL, we tested a battery of tissue-culture-adapted and ascitic-myelomacell lines in this system. The data in Table VIII show that tissue-culture-adapted or ascitic MOPC 315 cells can be consistently suppressed when incubated with TNP2aKLH and TNP-specific CTL. However, under identical conditions, S 107 (IgA, r; anti-phosphorylcholine) and MPC 11 (IgG2b, ~¢; of unknown specificity) tissueculture-adapted lines, and TEPC 15 (IgA, r; anti-phosphorylcholine) and MOPC 104E (IgM, ~k, anti-dextran) ascitic cells are not significantly inhibited. In all these experiments, antigen alone or TNP-specific CTL alone are nonsuppressive. Moreover, all the myeloma cell lines tested, when directly haptenated, can be lysed by syngeneic TNP-specific CTL in ~lCr-release assays. Finally, when mixtures of MOPC 315 cells Assay for cytolysts of 51Cr-laheled TNP-and DNP-P 815 targets speofic lysls of:t:
A.K ABBAS, S E RATNOFSKY, AND S J BURAKOFF
Effector cells TNP-P 815 at E T DNP-P 815 at E T 105 MOPC 315 cells were cultured for 24 h with or wtthout antigens and 1,500-rad x-irradiated BALB/c effector cells that were generated by subcutaneous priming and m wtro boosting. Data are expressed as m Table II , groups showing slgmficant mhibluon are ltahclzed * NS, not sigmficant (P > 0 1) Spontaneous SICr-release was < t 5%.
and MPC 11 cells are cultured with TNP-KLH and syngeneic TNP-specific CTL, only IgA secretion is suppressed (data not shown), indicating that there is no bystander effect on the non-TNP-receptor-bearing, IgG-producing MPC 11 targets. The inability to suppress non-TNP-binding myelomas in the presence of TNP-KLH cannot be simply attributed to differences in total binding of antigen to the myeloma cells, because, at least over 1-2 h, approximately equivalent amounts of antigen are bound to all the ussue-culture-adapted lines or the ascitic lines tested at the same concentration (Table VIII B) . In cold-antigen-competition experiments, we have found that the binding of ~25I-TNP-KLH to MOPC 315 cells can be inhibited by 34-48% in the presence of a 10 fold higher concentration of unlabeled TNP52BGG, which is similar to previously published results (27) . In contrast, the binding of 125I-TNP-KLH to non-TNP-binding myelomas can only be blocked by 10-20% with cold TNPs2BGG, implying that much of this binding is not to hapten-specific surface receptors. Nonspecific binding of ~2~I-labeled hapten proteins to tumor targets has been observed by other investigators, although the biochemical explanation for this is unknown. For instance, Bystryn et al. (29) found comparable binding of 125I-DNP-BSA to MOPC In A, 10 s BALB/c myeloma cells were cultured m triphcate with TNP-KLH and 3 × 105 1,500-rad xirradiated BALB/e anti-TNP effector lymphocytes for 24 h and then assayed for antibody secreuon Data are normahzed and expressed as the percent suppression of PFC compared to groups lacking effeetor cells In all experiments, TNP-KLH alone had no significant effect on PFC All the myeloma hnes have been tested at least three times. Statistically slgmficant results (P < 0 05 m each expenment) are ltahcmed. In B, the same tumor lines were incubated with ~mI-TNP2aKLH for 1 h (asciuc cells) or 2 h (tassue-culture-adapted hnes) at 37°C, washed, and the cell-bound radioactivity measured Each cell hne has been assayed two to six umes * ND, not done 315 cells and control cells that lack receptors for DNP in the absence of unlabeled carrier protein. The important result relevant to the present experiments is that such nonspecific binding does not permit TNP-specific CTL to interact with non-TNPbinding myeloma targets. In fact, TNP-specific CTL suppress MOPC 315 cell function when soluble-antigen concentrations are as low as 10 #g/ml (Table II and  Table VIII ), but fail to suppress the non-TNP binding myelomas even at a fivefoldhigher antigen concentration. These results indicate that TNP-KLH bound only to TNP-specific receptors sensitizes target cells so as to render them suppressible by TNP-reactive CTL.
As an additional approach to this question, we tested the ability of ABA-KLH and the double conjugate TNP-ABA-KLH to sensitize tissue-culture-adapted MOPC 315 cells for suppression by ABA-specific CTL. As shown in Table IX , TNP-specific CTL in the presence of TNP-KLH, but not ABA-KLH, suppress MOPC 315 cells, whereas ABA-reactive CTL are ineffective even in the presence of 100 #g/ml of ABA-KLH or TNP-KLH. This phenomenon is also not evidently attributable to the total amount of antigen bound to myeloma targets, because at 50 and 100 #g/ml, the amount of ABA-KLH bound/105 MOPC 315 cells in 1 h is 183.6 and 245.1 ng, respectively.Thus, the total amount of ABA-KLH bound to the cells at 100 #g/ml is greater than the amount of TNP-KLH bound at 10/~g/ml and roughly comparable to the amount of TNP-KLH bound at 50 #g/ml. However, when MOPC 315 cells are incubated with the double conjugate TNP-ABA-KLH so that the ABA determinant is bound to Assays for cytolysls of 51Cr-labeled, TNP-and ABA-modified P 815 targets specific lysis of~:
Effector cells TNP-P 815 at E.T ABA-P 815 at E:T Table II . * NS, not sigmficant (P > 0 1) Spontaneous 5'Cr-release was <20%.
TNP-specific receptors, they become susceptible to suppression by both TNP-specific and ABA-specific CTL (Table IX) . This experiment provides strong confirmation for the central role of binding of antigens to specific receptors in this phenomenon.
Effect of TNP-spec~c CTL on Pnmao, Antz-TNP Antibody Responses.
Preliminary experiments have shown that TNP-specific CTL generated in vitro and in vivo markedly suppress the primary antibody response of normal syngeneic spleen cells to TNP-KLH in vitro (Table X) . The effector cells are radiation insensitive, and their precursors are resistant to treatment with Cyclo; and unstimulated lymphocytes from Cyclo-pretreated mice have no effect on anti-TNP PFC. In other experiments, we have found that the effector cells are Thy-l.2-bearing T cells, and they cannot be bound to plastic dishes coated with TNP52BGG (data not shown). Studies are now in progress to define the cellular target of these hapten-specific CTL; i.e., whether they act on antigen-presenting cells, helper T lymphocytes, or B cells; and the role of H-2-encoded determinants in this phenomenon.
Discussion
Our results demonstrate that BALB/c TNP-reactive effector cells interact with a syngeneic TNP-binding myeloma, MOPC 315, in the presence of a soluble TNPprotein conjugate, the interaction being manifested as a reduction in antibody secretion by the myeloma targets. The effector cells are hapten-specific and H-2-restricted, Thy-l-bearing, Ly-2-positive T cells, and they only recognize myeloma targets that bind the hapten-proteins to specific surface receptors.
One of the initial questions raised by these experiments is the nature of the effector cells and precisely what effect they have on the myeloma targets. Although in vitro stimulation of lymphocytes with TNP-modified syngeneic cells generates not only CTL but hapten-specific suppressor T cells as well (8), the phenotypic characteristics of the effect cells detected in our system are typical of CTL. Thus, the cells are radioresistant, and their precursors are insensitive to Cyclo treatment (Table II) . Secondly, the hapten specificity of DNP-and TNP-reactive CTL, as measured by 51Cr release, closely parallels the specificity of these same cells as far as interaction with MOPC 315 cells in the presence of DNP-KLH and TNP-KLH is concerned (Table VII) . Thirdly, the effector cells cannot be bound to TNP-protein-coated plastic dishes (data not shown) under conditions that have been shown to bind a variety of hapten-and idiotype-specific suppressor T cells but not CTL (17, 30, 31) . Finally, TNP-specifie CTL generated in vivo (25) also inhibit MOPC 315 cells in the presence of TNP-KLH, albeit to a lesser degree than effectors induced in vitro, probably because the in vivo protocol induces relatively weak CTL (data not shown). Taken together, these data support the view that the effector cells that inhibit MOPC 315 targets in the presence of TNP-KLH are TNP-specifie CTL. Our inability to detect significant lysis of myeloma targets after this coculture by 5XCr-release assays or by dye exclusion is probably because these latter techniques are relatively insensitive and measure late consequences of CTL-target interactions In fact, functional inactivation of myeloma targets may be an early effect of CTL and has been used as a highly sensitive assay for classical, alloreactive CTL (19, 20) . It is also noteworthy that the 51Cr-release assay we have utilized is only a 4-h assay, whereas cocultures that are undertaken to measure effects on myeloma cell function are done for 24 h. So far, we have been unable to do 24-h SlCr-release assays because of high spontaneous release of ~lCr from the myeloma targets. In any event, it is likely that the myeloma targets that are incubated with soluble TNP-KLH and TNP-specific CTL, and that show inhibition of antibody secretion, are committed to lyse, and the reduced viable-cell recoveries after 2-3 d of reculture are consistent with this view.
Irrespective of the ultimate fate of myeloma cells, the ability of hapten-reactive CTL to inhibit myeloma function in the presence of soluble hapten-protein conjugates has several important implications. One central observation is that only myeloma cells that bind the hapten to specific surface receptors are susceptible to such regulation, implying that receptor-bound antigen forms an essential component of the target moiety recognized by the T cells. This is clearly different from the results of Schmitt-Verhulst et al. (9) and Ballas and Henney (10) , who have shown that only with H-2 k mice, soluble TNP-protein conjugates can generate TNP-reactive, H-2-restricted CTL and sensitize a variety of non-TNP-binding tumor targets for lysis by such CTL. In our studies, with H-2 a effectors and targets, only the TNP-binding myeloma MOPC 315 serves as a target for TNP-specific CTL in the presence of TNP-KLH (Table VIII A) . Moreover, ABA-specific CTL do not affect myeloma function in the presence of ABA-KLH (Table IX) , and these findings cannot be attributed to significant quantitative differences in the binding of different antigens to the myeloma targets. Most strikingly, ABA-specific CTL do interact with MOPC 315 cells in the presence of the double conjugate TNP-ABA-KLH, strongly indicating that binding of antigens to specific surface receptors is necessary to render the cells suppressible by hapten-reactive CTL. The second key observation is that the TNP-reactive CTL are H-2 restricted, in that only H-2 a effectors inhibit MOPC 315 cells (Table V) and only TNP-modified H-2 a cold targets are effective blockers (Table VI) . This result is consistent with the view that H-2-encoded surface determinants constitute another component of the target structure recognized by hapten-reactive CTE, similar to the proposed interaction of virus-or hapten-reactive CTL with appropriate virus-infected or hapten-modified syngeneic targets (7, 32) . Thus, it appears that TNP-specific CTL recognize TNP-KLH bound to specific receptors on MOPC 315 cells in association with H-2-encoded antigens, and this lymphocyte-target cell interaction leads to a detectable inhibition of antibody secretion by the myeloma cells. In B lymphocytes, it is clear that surface immunoglobulin and H-2 antigens are independent surface macromolecules (33) , and it is likely that immunoglobulin receptors for antigen and H-2 determinants on myeloma cells are also not directly linked in any fashion. Our results, therefore, imply that two independent membrane moieties, viz., receptorbound ligand and H-2 antigens, can be recognized as one functional unit by T cells. Because both antigen receptors and H-2 antigens are freely mobile in the plasma membrane, it is conceivable that they come into intimate association after antigen binding. These results, therefore, do not shed any light on whether the receptor on the T cell recognizes target structures as one or two entities, and, hence, whether the functional T cell receptor has a dual specificity for antigen (or hapten) and H-2 determinants or a single specificity for modified H-2 determinants.
Finally, these experiments provide the first direct demonstration of recognition of receptor-bound antigens by H-2-restricted T lymphocytes. To the extent that myeloma cells are analogous to normal B lymphocytes and antibody-secreting cells (11, 12) , these results imply that associative recognition of H-2 determinants and of antigen on specific B cells may be an important mechanism whereby antigen-reactive T ceils regulate immune responses specifically. Preliminary experiments (Table X) do indicate that TNP-specific CTL can regulate an anti-TNP antibody response in vitro, although we have not yet formally established the cellular targets of such CTL. Clearly a similar mechanism is likely to be operative in situations where H-2-restricted, antigen-specific T cells interact with other antigen-specific immunocompetent cells, such as the postulated 1-region-restricted collaboration between antigen-specific helper T and B lymphocytes (5, 6) . The myeloma system provides a model for exploring in greater depth the mechanisms of and requirements for regulatory interactions between T lymphocytes and other immunocompetent cells m which both cell types are H-2 restricted and antigen specific. Summary BALB/c splenocytes stimulated in vitro with trinitrophenyl (TNP)-modified syngeneic cells inhibit the secretion of antibody by the TNP-binding BALB/c myeloma MOPC 315 in the presence of soluble TNP-Keyhole limpet hemocyanin (KLH). The effector cells are hapten-specific, H-2-restricted, Thy-l.2-bearing, Ly-2-positive T lymphocytes whose precursors are resistant to pretreatment with cyclophosphamide. These phenotypic properties are typical of hapten-specific cytolytic T lymphocytes (CTL). The TNP-reactive CTL that inhibit MOPC 315 cells fail to suppress H-2 d myelomas that do not bear TNP-specific surface receptors, and this is not attributable to differences in total binding of TNP-KLH to the different myeloma cells. Moreover, azobenzene arsonate (ABA)-specific CTL inhibit MOPC 315 cells in the presence of the double conjugate TNP-ABA-KLH, but not in the presence of soluble TNP-KLH or ABA-KLH. These results show that H-2-restricted, hapten-specific lymphocytes regulate the function of myeloma cells that bind the hapten only to specific surface receptors, and provide a model for associative recognition of surface H-2 determinants and receptor-bound antigen. The results are discussed with reference to the mechanisms of T lymphocyte-target cell interactions, and the possible physiologic role of hapten-reactive CTL in specifically regulating anti-hapten antibody responses.
